Non-small cell lung cancer, epidermal growth factor receptor, tyrosine kinase inhibitors, exon 20 mutation, Osimertinib
non-small cell lung cancer, neoadjuvant chemoimmunotherapy, radiomics, deep learning, habitat imaging, Longitudinal CT
Osimertinib, Non-small cell lung cancer, TDM, case series
pembrolizumab, pharmacokinetics, modeling and simulation, cost-effectiveness